Veterinary World

     Open access and peer reviewed journal  

ISSN (Online): 2231-0916


Home l Editorial board l Instructions for authors l Reviewer guideline l Open access policy l Archives l FAQ

Open Access

Copyright: The authors. This article is an open access article licensed under the terms of the Creative Commons Attribution License

( which permits unrestricted use, distribution and reproduction in any medium, provided the work is properly cited.

Research (Published online: 15-10-2015)

6. Comparative study on the immunopotentiator effect of ISA 201, ISA 61, ISA 50, ISA 206 used in trivalent foot and mouth disease vaccine - Ehab El-Sayed Ibrahim, Wael Mossad Gamal, Amr Ismail Hassan, Safy El-Din Mahdy, Akram Zakria Hegazy and Magdy Mahmoud Abdel-Atty

Veterinary World, 8(10): 1189-1198



   doi: 10.14202/vetworld.2015.1189-1198


Ehab El-Sayed Ibrahim: Department of Foot and Mouth Disease, Veterinary Serum and Vaccine Research Institute, Abbasia, Cairo, Egypt;

Wael Mossad Gamal: Department of Foot and Mouth Disease, Veterinary Serum and Vaccine Research Institute, Abbasia, Cairo, Egypt;

Amr Ismail Hassan: Department of Foot and Mouth Disease, Veterinary Serum and Vaccine Research Institute, Abbasia, Cairo, Egypt;

Safy El-Din Mahdy: Department of Foot and Mouth Disease, Veterinary Serum and Vaccine Research Institute, Abbasia, Cairo, Egypt;

Akram Zakria Hegazy: Department of Foot and Mouth Disease, Veterinary Serum and Vaccine Research Institute, Abbasia, Cairo, Egypt;

Magdy Mahmoud Abdel-Atty: Department of Foot and Mouth Disease, Veterinary Serum and Vaccine Research Institute, Abbasia, Cairo, Egypt;


Received: 14-05-2015, Revised: 29-08-2015, Accepted: 03-09-2015, Published online: 15-10-2015


Corresponding author: Ehab El-Sayed Ibrahim, e-mail:

Citation: Ibrahim EE, Gamal WM, Hassan AI, Mahdy SE, Hegazy AZ, Abdel-Atty MM (2015) Comparative study on the immunopotentiator effect of ISA 201, ISA 61, ISA 50, ISA 206 used in trivalent foot and mouth disease vaccine, Veterinary World 8(10): 1189-1198.

Aim: A comparison study was conducted to explore the best internationally available adjuvant that could be used in production of a highly potent foot and mouth disease (FMD) vaccine, that could stimulate a strong immune response and possibly give greater protection against FMD.

Materials and Methods: Four experimental batches of trivalent FMD vaccine were prepared with different available oil adjuvants which included Montanide ISA 201, 206, 61 and 50.

Results: The results indicated that vaccines emulsified using Montanide ISA 201 and Montanide ISA 206 adjuvants elicited a protective humoral immune response from the 2nd week postvaccination (WPV) as for ISA 201 with serum neutralization test (SNT) and enzyme-linked immune sorbent assay (ELISA) antibody titers of 1.620.047a and 1.80.049a, 1.590.076a and 1.8360.077a, and 1.710.06b and 1.960.074b for serotypes O, A, SAT2, respectively, and for ISA 206 at SNT and ELISA antibody titers of 1.50.082a and 1.840.084a, 1.560.037a and 1.8180.052a, and 1.50.106a,b and 1.810.104a,b for FMD virus serotypes O, A and SAT2, respectively. For ISA 61 and ISA 50, the protective antibody titer appeared in the 3rd WPV. In the ISA 61 FMD vaccine, SNT and ELISA titer were 1.590.076a and 1.90.094a, 1.530.056a and 1.830.070a, and 1.50.082a and 1.840.094a for serotypes O, A and SAT2, respectively, and in the case of ISA 50 FMD vaccine, the SNT, and ELISA titer were recorded for serotypes O, A and SAT2 respectively, 1.590.037a and 1.80.030a, 1.680.056a,b and 1.9160.065a,b, and 1.650.082a and 1.90.09a. On estimating the cellular immune response, the highest delta optical density levels for ISA 201 (0.395-0.460) and ISA 206 (0.375-0.428) were observed on 14 and 21 days post vaccination (DPV) respectively, while the highest levels of lymphoproliferation for ISA 61 (0.375-0.455) and ISA 50 (0.411-0.430) were on 21 and 28 DPV, respectively.

Conclusion: The duration of immunity from Montanide ISA oils (201, 206, 61 and 50) FMD vaccines is a long-lived immunity which ranged between 32 and 38 weeks post vaccination but the Montanide ISA 201 FMD vaccine is superior to the others in the rapid cellular immune response of the vaccinated animals which showed its highest level within 14 days post vaccination.

Keywords: cellular immunity, FMD Montanide ISA vaccines, SNT, ELISA.

1. Depa, P.M., Dimri, U., Sharma, M.C. and Tiwari, R. (2012) Update on epidemiology and control of foot and mouth disease – A menace to international trade and global animal enterprise. Vet. World, 5(11): 694-704.
2. Longjam, N., Deb, R., Sarmah, A.K., Tayo, T., Awachat, V.B. and Saxena, V.K. (2011) A brief review on diagnosis of foot and- mouth disease of livestock: Conventional to molecular tools. Vet. Med. Int., 2011: 905768.
3. Rodriguez, L.L. and Grubman, M.J. (2009) Foot and mouth disease virus vaccines. Vaccine, 27 Suppl 4: D90-4.
4. Daoud, H.M., Ibrahim, E.E., El-Din, W.M.G. and Hassanin, A.I.H. (2013) Preparation of foot and mouth disease trivalent vaccine type A, O, SAT2 and determination of the Guinea pig protective dose 50 (GPPD50). Vet. World, 6(11): 844-851.
5. Ibrahim, E.E. (2011) Advanced studies on Foot and Mouth Disease Vaccines of sheep in Egypt. PhD.Sc. Thesis (Infectious Diseases), Faculty of Veterinary Medicine, Cairo University, Egypt.
6. Dara, P., Kalaivanana, R., Sied, N., Mamo, B., Kishore, S., Suryanaraya, V.V. and Kondabattula, G. (2013) Montanide ISATM 201 adjuvanted FMD vaccine induces improvedimmune responses and protection in cattle. Vaccine J., 31: 3327-3332.
7. Patil, P.K., Boyry, J., Ramoikrishna, C., Hugar, B., Misrol, L.D. and Natarajan, C. (2002) Immune response of goats against FMD quadrivalent vaccine: Comparison of double oil emulsion and aluminium hydroxide gel vaccine in eliciting immunity. Vaccine, 20: 2671-2789.
8. Alexandersen, S., Zhang, Z., Donaldson, A.I. and Garland, A.J. (2003) The pathogenesis and diagnosis of foot and mouth disease. J. Comp. Pathol., 129: 1-36.
9. Sutmoller, P. and Gaggero, A. (1965). Foot-and mouth diseases carriers. Vet. Rec., 77: 968-969.
10. Aidaros, H.A. (2002) Regional status and approaches to control and eradication of FMD in the Middle East and North Africa. Rev. Sci. Tech. Off. Int. Epizoot., 21(3): 451-458.
11. Farag, M.A., Aggour, M.A. and Daoud, A.M. (2005) ELISA as a rapid method for detecting the correlation between the field isolates of foot and mouth disease and the current used vaccine strain in Egypt. Vet. Med. J. Giza., 53(4): 949-955.
12. Satya, P. (2009) Vaccination against foot-and-mouth disease virus: Strategies and effectiveness. Expert Rev. Vaccines, 8(3): 347-365.
13. Abed El-Rahman, A.O., Farag, M.A., El-Kilany, S., Ali, S.M. and Yazed, M.A. (2006) Isolation and identification of serotype O of foot and mouth disease virus from imported Bulls and its correlation to the current used vaccine strain O1/3/1993. Proceeding 3rd International Conference Veterinary Research Division. NRC, Cairo, Egypt, p91-100.
14. Shawky, M., Abd El-Aty, M., Fakry, H.M., Daoud, H.M., El-Sayed, I.E., Mossad, G.W., Rizk S.A., Abu-Elnaga, H., Mohamed, A.A., Abd El-Kreem, A. and Farouk, E.M. (2013) Isolation and molecular characterization of foot and mouth disease SAT2 virus during outbreak 2012 in Egypt. J. Vet. Adv., 3(2): 60-68.
15. Lombard, M., Pastoret, P.P. and Moulin, A.M. (2007) A brief of vaccines and vaccination. Rev. Sci. Tech., 26(1): 29-48.
16. Xuan, H., Li, Y., Fang, H. and Zheng, C. (2011) Establishment of persistent infection with foot and mouth disease virus in BHK21 cells. Virol. J., 8: 169.
PMid:21492421 PMCid:PMC3097150
17. Reed, L.J. and Muench, H. (1938) A simple method of estimating 50% end points. Am. J. Hyg., 27: 493-497.
18. Health Protection Agency. (2009) Complement fixation tests. Issue No.: 3 Issue date 11.12.09 Issued by: Standards Unit, Department for Evaluations, Standards and Training page 1 of 23.
19. Killington, P.A., Stokes, A. and Hierolzer (1996) Virology Methods Manual. Ch. 4. Academic Press, New York. p72-89.
20. Barteling, S.J. and Cassim, N.I. (2004) Very fast (and safe) inactivation of FMD virus and enteroiruses by a combination of binary ethylenimine and formaldehyde. Schudel, A., Lombard, M. editors. Control of Infections Animal Disease by Vaccination. Vol. 119. Kager, Basel. p449-455.
21. Ismail, A.H., El-Mahdy, S.A., Mossad, W.G., Abd El-Krim, A.S., Abou El-Yazid, M. and Ali, S.M. (2013) Optimization of the inactivation process of FMD virus serotype SAT-2 by Binary Ethyleneimine (BEI). J. Vet. Adv., 3(3): 117-124.
22. Gamil, M.A. (2010) Studies on the immune response of calves vaccinated inactivated bivalent FMD virus vaccine type O/1 and A/Egypt 2006. M.V.Sc. in Veterinary Science (Virology). Benha University.
23. OIE. (2013) OIE/FAO Foot-and-Mouth Disease Reference Laboratory Network, Annual Report, 2013.
24. Code of Federal Regulation of USA (1986). Animal and Animal Products 9/1986. Office of the Federal Register National Archives and Record Administration.
25. Ferreira, M.E.V. (1976) Prubade microneutralization poraestudies de anticueropos de la fibre aftosa. 13th Centropanamericano Fibre aftosa, (21/22): 17-24.
26. Voller, A., Bidwell, D. E., and Bartlett, A. (1976b). Microplate enzyme immunoassays for the immunodiagnosis of virus infections. In Manual of Clinical Immunology, Chapter 69, edited by N. Rose and H. Friedman, pp. 506-512. American Society for Microbiology.
27. Lee, L.F. (1984) Proliferative response of chicken B and T lymphocytes to mitogens. Chem. Regul. Immun. Vet. Med., 15: 44-52.
28. Bomford, R. (1997) Adjuvants in veterinary vaccines In: Mowat, N., Rweyemamu, M., editors. Vaccine Manual: The Production and Quality Control of Veterinary Vaccines for Use in Developing Countries. FAO, Rome. p277-284.
29. Dong Li, Chunxue Zhou, Daliang She, Pinghua Li, Pu Sun, Xingwen Bai, Yingli Chen, Baoxia Xie, Zaixin Liu (2013) The comparison of the efficacy of swine FMD vaccine emulsified with oil adjuvant of ISA 201 VG or ISA 206 VG, Journal of Biosciences and Medicines, 2013, 1, 22-25,
30. Barnett, P.V., Pullen, L., Warder, P. and Stathen R.(1998) International bank for FMD vaccine (preliminary studies on emergency FMD vaccines formulated with Mantonide IMS (immnuosol), a new concept in oil adjuvant), European commission for the control of FMD, Aldershot, United Kingdom,14-18, September, Appendix, 37: 268-271.
31. Fakhry, H.M., Rizk, S.A., Abu-Elnaga, H.I., Deghaidy, W., Talaat, A.A. and Hegazi, A.Z. (2012) Field application of bivalent foot and mouth disease vaccine adjuvanted with Montanide ISA (25, 50, 206) and IMS (1113-3015) as an alternative to aluminum hydroxide gel. Egypt. J. Virol., 9(1): 123-136.
32. Knudsen, R.C., Groocock, C.M. and Andersen, A.A. (1979) Immunity to foot-and-mouth disease virus in guinea pigs: Clinical and immune responses. Infect. Immun., 24(3): 787-792.
PMid:223986 PMCid:PMC414375
33. Sharma, S.K. (1984) Foot and mouth disease in sheep and goat. Vet. Res. J., 4(1): 1-21.
34. El-Watany, H., Shawky, M.M., Roshdy, O.M. and El-Kelany, S. (1999) Relationship between cellular and humoral immunity responses in animal vaccinated with FMD vaccine. Zagazig Vet. J., 27(1): 49-57.
35. Mansour, A. (2001) Some studies on the effect of mycotoxins on immune response of FMD vaccinated animals. Ph. D. Thesis (Infectious Diseases). Faculty of Veterinary Medicine, Cairo University.
36. Samir, M.A.A. (2002) Studies on preparation of newly oil adjuvanted FMD vaccine. Ph. D. Thesis (Virology), Faculty of Veterinary Medicine, Cairo University.
37. El-Din, W.M., Ibrahim, E.E., Daoud, H. and Ali, S.M. (2014) Humeral and cellular immune response of Egyptian trivalent foot and mouth disease oil vaccine in sheep. Res. Opin. Anim. Vet. Sci., 4(4): 178-185.